<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856891</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-021</org_study_id>
    <nct_id>NCT04856891</nct_id>
  </id_info>
  <brief_title>A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis</brief_title>
  <acronym>EoDyssey</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess&#xD;
      the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients&#xD;
      with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind,&#xD;
      placebo-controlled treatment may have the option to receive 6 doses of open-label&#xD;
      lirentelimab (AK002) through the OLE Period of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Responders, where a responder is a patient achieving a mean peak duodenal eosinophil count ≤15 cells/3 duodenal hpf.</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean absolute change in 6 symptom total symptom score (TSS: abdominal pain, nausea, abdominal cramping, loss of appetite, fullness before finishing a meal, and bloating ) as measured by the PRO questionnaire (score from 0 none - 10 worst)</measure>
    <time_frame>Baseline to Weeks 23 - 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in tissue eosinophils</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving peak duodenal intraepithelial eosinophil count of ≤1 eosinophil/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment responders as defined by &gt;30% improvement in symptoms and mean eosinophil count ≤15 cells/hpf in 3 duodenal hpf</measure>
    <time_frame>At Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who show ≥50% reduction in TSS</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who show ≥70% reduction in TSS</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in weekly TSS over time</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Eosinophilic Duodenitis</condition>
  <condition>Eosinophilic Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>3.0 mg/kg of Lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK002</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.</description>
    <arm_group_label>3.0 mg/kg of Lirentelimab (AK002)</arm_group_label>
    <other_name>Lirentelimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. Male or female aged ≥18 and ≤80 years at the time of signing the informed consent for&#xD;
             entry.&#xD;
&#xD;
          3. Baseline endoscopic biopsy with ≥30 eosinophils/hpf in 3 hpf in the duodenum, as&#xD;
             determined by central histology assessment of biopsies collected during the screening&#xD;
             EGD + colonoscopy, without any other significant cause for the eosinophilia.&#xD;
&#xD;
          4. Completion of at least 4 daily PRO questionnaires per week for a minimum of 3 weeks&#xD;
             during screening.&#xD;
&#xD;
          5. A weekly average score of abdominal pain, nausea, or diarrhea ≥3 on the PRO&#xD;
             questionnaire (score from 0-10) for at least 2 weeks of screening and a weekly average&#xD;
             TSS of ≥10 for at least 2 weeks of screening.&#xD;
&#xD;
          6. Inadequate or loss of response to, or intolerant to standard therapies for EoD&#xD;
             symptoms, which could include PPI, antihistamines, systemic or topical&#xD;
             corticosteroids, and/or diet, among others.&#xD;
&#xD;
          7. If patient is on pre-existing dietary restrictions, willingness to maintain dietary&#xD;
             restrictions throughout the study.&#xD;
&#xD;
          8. Willing and able to comply with all study procedures and visit schedule including&#xD;
             follow-up visits.&#xD;
&#xD;
          9. Female patients must be either post-menopausal for at least 1 year with FSH level &gt;30&#xD;
             MIU/mL at screening or surgically sterile (tubal ligation, hysterectomy, or bilateral&#xD;
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative&#xD;
             pregnancy test and agree to use dual methods of contraception, or abstain from sexual&#xD;
             activity from screening until the end of the study, or for 120 days following the last&#xD;
             dose of study drug, whichever is longer. Male patients with female partners of&#xD;
             childbearing potential must agree to use a highly effective method of contraception&#xD;
             from screening until the end of the study or for 120 days following the last dose of&#xD;
             study drug, whichever is longer. All fertile men with female partners of childbearing&#xD;
             potential should be instructed to contact the Investigator immediately if they suspect&#xD;
             their partner might be pregnant (e.g., missed or later menstrual period) at any time&#xD;
             during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of systemic or topical corticosteroids exceeding the equivalent of 10 mg/day&#xD;
             prednisone within 4 weeks prior to the screening visit.&#xD;
&#xD;
          2. Baseline endoscopic biopsy with ≥30 eosinophils/hpf in 5 hpf in the gastric mucosa as&#xD;
             determined by central histology assessment of biopsies collected during the screening&#xD;
             EGD.&#xD;
&#xD;
          3. Change in the dose of corticosteroids (systemic or topical), PPI, leukotrienes, or&#xD;
             diet therapy within 4 weeks prior to the screening visit.&#xD;
&#xD;
          4. Treatment with any immunosuppressive or immunomodulatory drugs that may interfere with&#xD;
             the study within 12 weeks prior to the screening visit.&#xD;
&#xD;
          5. Prior exposure to AK002 or known hypersensitivity to any constituent of the study&#xD;
             drug.&#xD;
&#xD;
          6. Active Helicobacter pylori infection, unless treated and confirmed to be negative by&#xD;
             repeat EGD (for baseline eosinophil count) prior to randomization and symptoms remain&#xD;
             consistent.&#xD;
&#xD;
          7. History of inflammatory bowel disease, other chronic inflammatory diseases in the&#xD;
             colon (with the exception of eosinophilic colitis), celiac disease, achalasia, or&#xD;
             esophageal surgery.&#xD;
&#xD;
          8. History of bleeding disorders and/or esophageal varices.&#xD;
&#xD;
          9. Other causes of duodenal eosinophilia or eosinophilic granulomatosis with&#xD;
             polyangiitis.&#xD;
&#xD;
         10. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
         11. Presence of an abnormal laboratory value considered to be clinically significant by&#xD;
             the Investigator.&#xD;
&#xD;
         12. Any disease, condition (medical or surgical), or cardiac abnormality, which, in the&#xD;
             opinion of the Investigator, would place the patient at increased risk.&#xD;
&#xD;
         13. History of malignancy, except carcinoma in situ, early stage prostate cancer, or&#xD;
             non-melanoma skin cancers. However, patients with cancers that have been in remission&#xD;
             for more than 5 years and are considered cured can be enrolled.&#xD;
&#xD;
         14. Treatment for a clinically significant helminthic parasitic infection within 6 months&#xD;
             of screening.&#xD;
&#xD;
         15. Positive helminthic infection on Ova and Parasite (O&amp;P) test.&#xD;
&#xD;
         16. Seropositive for Strongyloides stercoralis at screening.&#xD;
&#xD;
         17. Seropositive for HIV or hepatitis at screening, except for vaccinated patients or&#xD;
             patients with past but resolved hepatitis, at screening.&#xD;
&#xD;
         18. Vaccination with live attenuated vaccines within 30 days prior to initiation of&#xD;
             treatment in the study, during the treatment period, or vaccination expected within 5&#xD;
             half-lives (4 months) of study drug administration. This exclusion criterion does not&#xD;
             apply to all types and formulations of vaccines (including live attenuated vaccines)&#xD;
             authorized by FDA or other regulatory authority for the prevention of COVID-19, which&#xD;
             may be administered before, during, or after the study.&#xD;
&#xD;
         19. Participation in a concurrent interventional study with the last intervention&#xD;
             occurring within 30 days prior to study drug administration (or 90 days or 5&#xD;
             half-lives, whichever is longer, for biologic products).&#xD;
&#xD;
         20. Known history of alcohol, drug, or other substance abuse or dependence that is&#xD;
             considered by the Investigator to be ongoing and clinically significant.&#xD;
&#xD;
         21. Any other reason that in the opinion of the Investigator or the Medical Monitor makes&#xD;
             the patient unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Paterson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Paterson, MD</last_name>
    <phone>(650) 597-5002</phone>
    <email>info@allakos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophil</keyword>
  <keyword>Eosinophilic</keyword>
  <keyword>Eosinophilic gastrointestinal disorders</keyword>
  <keyword>EGID</keyword>
  <keyword>EoD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Duodenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

